eRF3b Antibodies

Santa Cruz Biotechnology provides a broad selection of eRF3b monoclonal antibodies for investigating eRF3b in cellular processes. The monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). eRF3b, or eukaryotic release factor 3b, plays a critical role in the termination of protein synthesis by facilitating the release of newly synthesized polypeptides from the ribosome. eRF3b maintains the fidelity of translation and participates in various cellular stress responses. Research has shown that eRF3b significantly influences gene expression regulation and may have implications in diseases such as cancer. Scientists worldwide utilize eRF3b monoclonal antibodies to advance their understanding of translation termination mechanisms. Ongoing studies with eRF3b monoclonal antibodies continue to reveal new insights about protein synthesis regulation and cellular stress responses. Research conducted with Santa Cruz Biotechnology monoclonal antibodies contributes to expanding scientific knowledge about eRF3b's role in health and disease.